Inhibikase Therapeutics, Inc. (IKT): Total Liabilities
$8.30M
As of 2025-12-31
$10.26M
As of 2026-06-30
+28.6%
3-year compound annual growth
+10.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.30M | +122.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $3.73M | +5.8% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $3.53M | -9.5% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $3.90M | -3.8% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $4.05M | -18.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $5.00M | n/a | 2022-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $8.30M | +122.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $21.32M | +17.0% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $87.18M | +191.5% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $32.52M | +6.5% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $53.03M | +62.1% |
Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗